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Liver-directed gene therapy holds great promise for the treatment of 
inherited metabolic disease. Two strategies have emerged. Ex vivo gene 
therapy involves the transplantation of autologous hepatocytes transduced 
with recombinant retroviruses while in culture. The feasibility of this 
approach has been demonstrated in several animal models, and a human 
trial has been initiated. An alternative strategy uses recombinant viruses to 
deliver the transgene directly to hepatocytes in vivo. 
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Introduction 
Inbom errors of metabolism comprise a diverse group 
of rare, disabling disorders that collectively contribute to 
substantial morbidity in our society. A large number of 
these disorders are caused by defects in enzymes that are 
primarily expressed in the liver and which are involved 
in intermediary metabolism [ 1 ]. Three examples include: 
ornithine tmnscarbamylase deficiency (OTCD), which is 
characterized by an accumulation of ammonia leading to 
episodes of coma; familial hypercholesterolemia (FH), 
which is caused by a defect in low density lipoprotein 
(LDL) receptor and is characterized by an extreme ele- 
cation in LDL cholesterol leading to the development of 
premature coronary heart disease; and phenylketonuria 
(PKU), which is caused by a defect in phenylalanine 
hydroxylase and is characterized by mental retardation if 
not properly managed. Several strategies have been de- 
veloped for treating inborn errors of metabolism: first, 
counseling and/or patient education; second, metabo- 
lite in tervent ion either by pharmacologic replacement of 
the product, dietary restriction, or by utilizing an alterna- 
tive enzymatic pathway; third, activation or replacement 
of the dysfunctional protein; and finally, organ transplan- 
tation to replace the defective liver function. Despite ex- 
tensive research in the development of these and other 
innovative therapies most of these diseases are essentially 
refractory to anything except palliative therapy. 
Several metabolic diseases have been treated by or- 
thotopic liver transplantation. In many situations, this 
was performed in an attempt to treat secondary con- 
sequences of the primary molecular defects that lead 
to generalized destruction of liver function. However, or- 
thotopic liver wansplantation has also been indicated in 
lethal metabolic diseases as a means of correcting the pri- 
mary genetic defect in liver function. In this application, 
the liver is structurally normal and the transplant is per- 
formed to replace a single defective metabolic derange- 
ment Orthotopic liver transplantation for metabolic dis- 
ease has been performed in a limited number of patients 
with the following diseases: FH, 0t-l-antitrypsin deficiency, 
Crigler-Najjar syndromel; and a few glycogen-storage dis- 
eases [2]. In pediatric cases, the five-year survival rate 
following liver transplantation for metabolic diseases is 
approximately 83%. Mortality can occur in the perioper- 
ative period, while chronic immunosuppressive therapy 
and the ever-present threat of rejection contributes to 
ongoing morbidity. Because of these unavoidable com- 
plications, it is difficult to justify a liver transplant in all but 
the most severe conditions. A more attractive approach 
would be to establish methods for selectively reconstitut- 
ing the expression of the functional gene in the liver by 
somatic gene therapy. 
An alternative approach to organ transplantation is e x  
v ivo gene therapy. The process of e x  v ivo gene trans- 
fer entails harvesting the appropriate tissue, isolating the 
target cell, growing the cells in vitro, introducing the 
gene of interest into the cells with recombinant retro- 
viruses, and placing the genetically modified cells back 
into the patient from which they were derived. An im- 
portant early paradigm of e x  v ivo gene therapy has 
been strategies based on the transplantation of geneti- 
cally modified hepatocytes. 
The first step of liver-directed e x  v ivo gene therapy is the 
isolation of viable hepatocytes from biopsied tissue. Im- 
portant limitations in the process of e x  vivo gene therapy 
directed to the liver is the inability to expand isolated 
hepatocytes in culture. It is possible to establish primary 
cultures but impossible to passage these cells. Thus, to 
obtain therapeutic quantities of hepatocytes for genetic 
modification, it is necessary to resect significant portions 
of tissue and genetically modify the cells soon after iso- 
lation. 
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Hepatocyte isolation 
Hepatocytes have been isolated from a variety of species 
including mouse, rat, rabbit, dog, baboon and human 
tissue [3,4,5-*,6,7",8.,9-',10-16]. The general approach 
is to perfuse liver tissue with a neutral protease to re- 
lease individual cells. Fractions of cells enriched for hep- 
atocytes are obtained by differential sedimentation. The 
enriched suspension of hepatocytes are plated in culture 
and cultivated in a hormonally defined media. (See the 
references [3,4,5",6,7",8-,9"*,10-17] both for examples 
of the numerous species from which hepatocytes have 
been isolated, and for published experiences of the 
isolation and in vitro cultivation of hepatocytes.) De- 
spite strategies for enrichment, hepatocyte cultures are 
never pure; one frequently recovers cultures that con- 
rain greater than 95% hepatocytes but there are always 
a number of contaminating cells within these cultures 
(e.g., endothelial cells, Kupffer cells, ito cells or biliary 
epithelial cells). The quality of hepatocyte preparations, 
which is most frequently measured in terms of total yield 
and viability, varies considerably. 
Extensive literature exists on the primary cultivation of 
hepatocytes in vitro. A variety of conditions have been es- 
tablished for maintaining hepatocytes in culture. Despite 
tremendous efforts it has been impossible to establish 
conditions necessary to passage and expand adult hepa- 
tocytes. In addition, it is difficult to maintain the differen- 
tiated state of the cells for prolonged periods in culture. 
In a typical experiment, hepatocytes can be maintained 
in culture for approximately 14 days, during which time 
the cells undergo several rounds of cell division. 
Gene transfer into hepatocytes using 
retroviruses 
Several approaches have been developed for transfer- 
ring genes into cultured hepatocytes. The traditional 
approaches of transfection such as calcium phosphate 
transfection, electroporation, and lipofection have been 
used; however, expression of the recombinant gene has 
been extremely low and transient [ 18--21]. Furthermore, 
these approaches are associated with substantial in vitro 
toxicity. The most successful strategy has been to use re- 
combinant retroviruses. 
Retroviruses are enveloped viruses containing a single- 
stranded RNA genome [22]. A typical retrovirus ex- 
presses three essential structural genes: gag, encoding 
a collection of proteins involved in virus assembly; pot  
encoding a multifunctional protein containing several ac- 
tivities including reverse transcriptase and an integrase; 
and env, encoding a glycoprotein that spans the enve- 
lope and contains a domain on the surface of the virion 
that is recognized by a cell surface receptor. Retroviruses 
bud from the surface of infected cells in a non-lytic man- 
ner. Infection begins with endocytosis of the virus and 
delivery of the RNA genome into the cytoplasm through 
a fusion event between the virion envelope and the 
membrane of the endosome that is mediated by the 
fusigenic envelope protein. The RNA is converted to a 
double-stranded DNA intermediate through the sequen- 
tial activity of reverse tmnscriptase, RNase H, and DNA 
polymerase. The DNA is very efficiently integrated into 
the genome of the recipient cell in a relatively ran- 
dom manner. The integrated form of the virus, called 
the provirus, contains repeated sequences, termed long 
terminal repeats (LTRs), at both ends. The provirus con- 
rains a single transcriptional unit that is initiated at the 5' 
LTR. This full-length transcrfpt, called the genomic RNA, 
has two functions: first, it contains a sequence, caUed 4, 
that enables it to be packaged into virions; and second, 
it can be translated, yielding the Gag and Pol proteins. 
The genomic transcript undergoes processing to form 
the subgenomic transcript that can be translated into the 
Env protein. 
Several strategies have been suggested for using retro- 
viruses to transduce recombinant genes. One approach 
is to splice a recombinant gene into a complete retroviral 
genome. The resulting recombinant virus will transduce 
the recombinant gene; however, it will remain infectious, 
with recipient cells producing recombinant viruses. Sev- 
eral investigators have suggested strategies for generating 
recombinant retroviruses that are replication defective. 
The general approach is to generate a packaging .cell 
line that can provide in t r a m  all the proteins neces- 
sary to form virions. This is accomplished by transfecting 
into a mouse fibroblast cell line a retroviral genome from 
which the ~ sequences have been deleted. The genomic 
transcript can express gag, poland eng  however, it.is not 
packaged into virions. A cell line that produces recombi- 
nant virus is generated by transfecting into the packaging 
cell line a retroviral vector in which the gag, pol  and env 
sequences have been replaced with a recombinant gene. 
The genomic transcript from the retroviral vector con- 
rains ~ sequences, and thus it is incorporated into virions 
of the packaging cell line. Resulting viruses transduce the 
recombinant gene and are replication-defective because 
they do not transduce gag, pol  and env. Packaging cell 
lines are available with different tropisms based on the 
envelope proteins that they express [23-25]. Ecotropic 
cell lines express viruses whose tropism is restricted 
to rodents, while virus from amphotropic cell lines have 
extremely wide host ranges and are capable of infecting 
most mammalian cells, including humans. 
A critical step in the development of ex  vivo gene therapy 
for the liver is to stably transfect a large proportion of cul- 
tured hepatocytes before transplantation of the corrected 
autologous cells. The limitations of primary hepatocyte 
cultures described above provide difficult challenges in 
achieving this. First, hepatocytes cannot be passaged, and 
thus selection and expansion of the transduced cells is 
not possible. Furthermore, the cells undergo few cell divi- 
sions and remain differentiated and viable for only a short 
period of ~ne. Therefore, gene transfer must occur dur- 
ing a short window after plating and it must be extremely 
efficient. The most promising approach has been with 
recombinant retroviruses. Wolff et aL [16] were the first 
to demonstrate transduction of hepatocytes using a neff 
expressing retrovirus and adult rat hepatocytes. Success- 
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ful transduction was further demonstrated using /acZ- 
expressing retroviruses in rat hepatocytes and neo-ex- 
pressing retroviruses with newborn mouse hepatocytes 
[13,15]. Under optimal circumstances it is possible to 
achieve transduction efficiencies that approach 30-50% 
with a single exposure to virus. It is critical that the 
cells are plated at subconfluent densities so that they 
can undergo at least one round of ceil division. The 
most important factor in achieving efficient gene trans- 
fer is the time after plating that the cells are exposed 
to virus. We and, others have identified a window be- 
tween 48-72 h after plating during which the cells are 
most susceptible to infection. The mechanisms for this 
are unclear; however it may relate, in part, to the fact 
that the cells are most actively cycling during this time. 
Retrovirus-mediated ge:ne transfer has now been demon- 
strated in cells from a variety of species including adult 
and' newborn mouse, rat, adult and newborn rabbit, 
dog, baboon, and human [6,7.,8*,11,14--16,26]. In ad- 
dition, a variety of potentially therapeutic recombinant 
genes have been transduced and expressed in hepato- 
cytes. These include genes expressing the LDL receptor, 
ornithine transcarbamylase, pheny~alanine hydroxylase, 
factor IX, and UDP glucuronosyltransferase (JM Wilson 
and F Askari, unpublished data)[4,5--,6,11,14,26]. 
Hepatocyte transplantation 
Strategies for harvesting and transplanting the genetically 
modified hepatocytes are currently being developed. For 
purposes of ex vivo gene therapy it is necessary to de- 
sign approaches that enable the ex  vivo manipulated 
cells to be efficiently harvested and transplanted, and 
allow the cells to stably engraft and continue express- 
ing the recombinant gene. Initial attempts to transplant 
hepatocytes used unmarked syngeneic cells that were in- 
troduced into sites such as the dorsal fat pad or spleen 
[27,28]. Long-term engraftment of these ceils was docu- 
mented by demonstrating persistence of cells with hep- 
atocyte morphology in the ectopic sites. These strategies 
are not suitable for therapeutic application because the 
number of cells that can be engrafted are extremely lim- 
ited. An approach of more relevance to gene therapy is 
to demonstrate correction of hepatocyte dysfunction by 
virtue of cell transplantation. This has been attempted 
in several animal models. Transplantation of syngeneic 
hepatocytes into the portal circulation of rats following 
90% partial hepatectomy resulted in improved survival, 
indicating short-term function of the cells until the rem- 
nant liver regenerated [29]. Rats genetically deficient in 
albumin achieved transient levels of detectable serum 
albumin when transplanted with allogeneic hepatocytes 
into the portal vein or peritoneal cavity [30]. The pro- 
duction of albumin was prolonged when the recipient 
was immunosuppressed or the donor cells were purged 
of macrophages. Stable correction of defective bilirubin 
metabolism was achieved in the Gunn rat transplanted 
with congenic hepatocytes [31]. Similar principles have 
been applied with transgenic mice [32-34]. Hepatocytes 
from animals carrying a aver-specific transgene have been 
transplanted into congenic recipients. Engraftment of the 
donor hepatocytes, detected by virtue of transgene ex- 
pression, has been demonstrated for at least one year. 
The first trials of hepatocyte transplantation in humans 
were conducted in Japan. Allogeneic hepatocytes were 
transplanted into the spleens of patients suffering from 
fulminant liver failure [35]. 
Lessons learned from models of hepatocyte transplanta- 
tion have now been applied to models of ex  vivo gene 
therapy. The major difference is that the cells used in the 
transplantation studies described above were freshly iso- 
lated, whereas those used in ex  vivo gene therapy must 
be cultured for at least three days - -  during their trans- 
duction with retroviruses - -  before they are harvested for 
transplantation. Anderson et a~ [3] achieved short-term 
engraftment of syngeneic hepatocytes that were trans- 
duced with a neo virus and transplanted onto a sponge 
implanted into the peritoneal cavity of rats. We have used 
the human disease FH as a model for developing ex  vivo 
gene therapies for the liver. The availability of an animal 
model of this disease, termed the Watanabe heritable 
hyperlipidemic (WHHL) rabbit, has been extremely use- 
ful in developing gene-therapy strategies. Transplantation 
of allogeneic hepatocytes transduced with a retrovirus 
containing the human LDL receptor gene into WHHL 
rabbits led to temporary amelioration of hypercholes- 
terolemia [14]. Loss of in vivo efficacy of the therapy 
was the result of destruction of the transplanted ceils, 
presumably because of an immune response directed 
at the allogeneic cells or the human LDL-receptor pro- 
tein. These problems were overcome in a second series 
of experiments in which autologous hepatocytes trans- 
duced with retroviruses containing a normal rabbit LDL- 
receptor gene were transplanted into the portal circula- 
tion of WHHL rabbits [5°°]. Recipient animals realized a 
prolonged improvement in serum cholesterol; analysis of 
liver tissue demonstrated high levels of recombinant-de- 
rived LDL-receptor RNA for the duration of the experi- 
ment (6.5 months). The practicality of this approach has 
been demonstrated in larger animals, including dogs and 
baboons [8o,9oo]. 
In vivo gene transfer using retroviruses 
Recent studies have demonstrated the feasibility of using 
recombinant retroviruses to deliver genes t o  hepatocytes 
in vivo [36]. The major problem is that hepatocytes 
are normally quiescent and efficient retroviral infection 
requires a population of target cells that are dividing. 
Hatzglou et a t  [37] injected recombinant viruses into 
the peritoneal cavity of developing rats at a time when 
the fetal liver is actively growing. Using a recombinant 
virus with a liver-specific promoter, they were able to 
demonstrate transduction of hepatocytes. Similar results 
have been achieved in adult rats when the virus is infused 
into animals following injury to the liver, such as partial 
hepatectomy, to stimulate cell division in the target hep- 
atocytes. Infusion of retrovirus into the portal circulation 
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of rats following partial hepatectomy resulted in stable 
transduction in a small population of hepatocytes based 
on PCR analyses [38]. The efficiency of hepatocyte trans- 
duction is increased 1-5% when the liver is temporar- 
ily devascularized and infused with virus 24 h after partial 
hepatectomy [39]. 
Conclusions 
Gene transfer directed to hepatocytes has emerged as an 
important early paradigm of gene-replacement therapies. 
R e c o m b i n a n t  re t rovi ruses  have  b e e n  u s e d  in b o t h  e x  v i vo  
a n d  in  v i vo  a p p r o a c h e s  to l iver-di rec ted  g e n e  therapies .  
T h e  rational and  feasibility o f  e x  v i vo  g e n e  the rapy  for  
liver me tabo l i c  d i sease  has  b e e n  es tabl i shed.  Whi le  this 
f o r m  o f  therapy  will p r o b a b l y  have  i m p o r t a n t  applica-  
t ions,  it is c o m p l i c a t e d  and  imprac t ica l  fo r  b r o a d  use. 
In addi t ion,  the  eff iciency is l imi ted  by  the  n u m b e r  o f  
a u t o l o g o u s  cells that can  b e  ha rves t ed  and  re - infused  
into  the  por ta l  circulat ion,  impor tan t ly ,  the  du ra t i on  o f  
therapeut ic  effect  ach ieved  us ing  this a p p r o a c h  is un- 
k n o w n  because  the  g e n e  is n o t  in se r t ed  into  a s t e m  
ceU. I n  v i vo  g e n e  the rapy  p r o v i d e s  t he  po ten t ia l  o f  m o r e  
efficient g e n e  t ransfer  and  the  feasibili ty o f  r e p e a t e d  treat- 
ments .  However ,  a p p r o a c h e s  for  s t imula t ing  h e p a t o c y t e  
divis ion that  a re  m o r e  pract ical  a n d  less  m o r b i d  than  par- 
tial h e p a t e c t o m y  will n e e d  to b e  d e v e l o p e d .  
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